Gluconato De Cálcio Labesfal

Gluconato De Cálcio Labesfal is an injectable solution containing calcium gluconate monohydrate as the active ingredient; the specific strength is not disclosed. Marketed in the European Union and available by prescription, this calcium supplement is administered intravenously to address calcium deficits. It belongs to the electrolyte replenishment class and is used under medical supervision for conditions requiring rapid calcium repletion. The product is supplied in a container suitable for infusion.

Gluconato De Cálcio Labesfal is indicated for clinical situations where calcium levels need to be restored quickly.

- Treatment of acute hypocalcemia confirmed by laboratory testing. - Management of calcium deficiency associated with parathyroid disorders. - Electrolyte replacement during major surgery or massive transfusion. - Support of cardiac function when calcium‑dependent contractility is compromised. - Adjunct therapy in patients receiving calcium‑channel blocker overdose (under specialist guidance). - Correction of calcium loss in patients with extensive burns or severe trauma. - Prevention of tetany in postoperative patients with low serum calcium.

Side effects reported with intravenous calcium gluconate vary in frequency and severity.

Common: - Transient redness or irritation at the injection site. - Mild nausea or a feeling of warmth during infusion. - Temporary low blood pressure (hypotension) that resolves spontaneously. - Slight increase in heart rate (tachycardia) without other symptoms.

Serious: - Severe hypercalcemia leading to confusion, muscle weakness, or cardiac arrhythmias. - Allergic reactions such as rash, itching, or swelling of the face and throat. - Rapid drop in blood pressure (shock) requiring immediate medical intervention. - Calcium precipitation in the bloodstream causing vascular occlusion (rare).

Before administering Gluconato De Cálcio Labesfal, clinicians should evaluate several precautionary factors to ensure safe use.

- Verify serum calcium levels and correct any underlying electrolyte imbalances. - Assess renal function, as impaired kidneys may reduce calcium clearance. - Avoid rapid infusion rates to minimize the risk of cardiovascular irritation. - Review patient history for hypersensitivity to calcium salts or related compounds. - Use caution in patients with cardiac disease, especially those prone to arrhythmias. - Monitor for signs of hypercalcemia during and after infusion. - Ensure compatible IV solutions are used to prevent calcium precipitation.

Calcium gluconate can interact with certain medications or solutions, influencing efficacy or safety.

Avoid: - Do not mix the injectable solution with phosphate‑containing intravenous fluids, because calcium phosphate precipitation can occur and obstruct catheters. - Avoid simultaneous administration of bisphosphonates, since calcium may bind to the drug and markedly reduce its oral absorption. - Refrain from giving calcium gluconate together with loop diuretics without close monitoring of serum calcium and renal function.

Use with caution: - Use with caution when patients are receiving digitalis glycosides; increased extracellular calcium can potentiate the drug’s cardiac effects and precipitate arrhythmias. - Monitor serum electrolytes closely if calcium gluconate is combined with thiazide diuretics, which can decrease urinary calcium excretion and raise calcium levels. - Adjust infusion rates and observe neuromuscular status when calcium gluconate is co‑administered with magnesium sulfate, as both ions influence muscle and nerve function.